Skip to main content
. 2023 Jul 13;23:349. doi: 10.1186/s12872-023-03167-1

Table 1.

Basic information of patients

Age (years) 74.15 ± 7.89[41–93]
Male, n (%) 74(59%)
Hypertension 68(54%)
Coronary heart disease 70(56%)
Diabetes 44(35%)
Old myocardial infarction 41(33%)
Myocardial ischemia 46(37%)
Lower extremity atherosclerosis 58(46%)
Cardiac function classification
Class III 56(44%)
Class IV 70(56%)
Lower extremity venous thrombosis 19(15%)
Interstitial venous thrombosis 14(74%)
Popliteal vein thrombosis 1(5%)
Femoral vein thrombosis 1(5%)
Deep vein thrombosis 1(5%)
Small saphenous vein thrombosis 1(5%)
Posterior tibial vein thrombosis 1(5%)
Anticoagulation therapy
Warfarin 39(31%)
New oral anticoagulants (rivaroxaban or dabigatran) 87(69%)
Laboratory data
BNP (pg/L) 1317.47 ± 929.09
D-DI (µg/L) 1.74 ± 1.37
vWF (%) 250.58 ± 88.05

Note: D-DI, D-dimer; BNP, B-type natriuretic peptide; vWF, von Willebrand factor